Brooke is an associate editor for The American Journal of Managed Care® (AJMC®). She joined AJMC in 2023, where she produces written content covering multiple disease states.
She has a BA in journalism from Seton Hall University. You can connect with Brooke on LinkedIn.
Medicaid Unwinding Left Thousands of Pediatric Patients Uninsured
During the unwinding of continuous Medicaid provisions, 8.7% of pediatric patients at community-based health organizations became uninsured, with higher rates among older children, females, and those with chronic medical conditions.
Physician Gaps in Genetic Testing Knowledge May Impact Ovarian Cancer Care
While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient access to genetic counseling.
Higher Psoriatic Arthritis Disease Burden Found Among Hispanic, Non-White Patients
Hispanic and non-White patients with psoriatic arthritis (PsA) had higher tender joint counts and greater disease severity, highlighting racial and ethnic disparities in PsA disease burden and treatment outcomes.
Niraparib Extends PFS, Time to Next Treatment in Patients With EOC, Especially BRCA-Mutated Cases
First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.
FDA Approves New Maintenance Dosing for Lecanemab to Treat Early-Stage Alzheimer Disease
The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer disease (AD), enabling a transition from biweekly to once-every-4-week dosing while preserving clinical and biomarker benefits.
Real-World Study Highlights PARP Inhibitor Challenges in Ovarian Cancer Care
Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for enhanced strategies to optimize postrecurrence treatment.
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Mind the Gap: Patient-Reported PsA Impact Scores, Physician Treatment Decisions Misaligned
While higher patient-reported Psoriatic Arthritis (PsA) Impact of Disease questionnaire (PsAID-12) scores were associated with treatment escalation, physicians primarily relied on clinical assessments when making treatment decisions.
Gynecologic Oncology Practices Evolve With Surgical De-Escalation Trends
Researchers identified a 15-year shift toward surgical de-escalation in gynecologic oncology, marked by fewer surgical interventions, increased adoption of minimally invasive techniques, and a greater focus on fertility preservation and sentinel lymph node procedures.
AI Outperforms Traditional Methods in Predicting Ovarian Cancer Surgery Outcomes
Artificial intelligence (AI) models, particularly artificial neural networks and machine learning, outperform traditional methods in predicting post–complete cytoreduction outcomes in patients with ovarian cancer, including overall survival, no residual disease, and postoperative complications.
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Niraparib Improves Outcomes in Patients With Stage III EOC, No Visible Residual Disease
Patients with stage III epithelial ovarian cancer (EOC) and no visible residual disease after primary cytoreductive surgery had significantly longer real-world progression-free survival and time to next treatment when treated with first-line maintenance niraparib compared with those with higher-risk disease.
Updated Guidelines Allow Men Who Have Sex With Men to Join National Blood Donor Month Efforts
Men who have sex with men (MSM) can now participate in National Blood Donor Month under the FDA's updated guidelines, marking a crucial step toward addressing blood shortages and promoting inclusivity.
Nomogram Predicts Overall Survival in Patients With Ovarian Cancer, Liver Metastases
Researchers developed and validated a nomogram to predict 1-, 2-, and 3-year overall survival (OS) in patients with ovarian cancer and liver metastases (OCLM), outperforming an external model in stability and accuracy.
Nurse-Led Care Improves Disease Activity in Rheumatoid Arthritis
Nurse-led care effectively reduces disease activity and improves self-efficacy in patients with rheumatoid arthritis, delivering comparable outcomes to rheumatologist-led care and usual care while easing health care burdens.